Table 4 Relation between CD133 and BCAT1 markers with clinical pathological features in TNBC patients
Clinicopathological criteria | No. of patients | BCAT1 n (%) | P | CD133 n (%) | P | ||
|---|---|---|---|---|---|---|---|
Low expression | High expression | Low expression | High expression | ||||
Age at diagnosis | Â | Â | Â | 0.25 | Â | Â | 0.802 |
 ≤ 49 | 154 | 113 (73.37%) | 41 (26.63%) |  | 103 (66.88%) | 51 (33.12%) |  |
 > 49 | 137 | 92 (67.15%) | 45 (32.85%) |  | 94 (68.61%) | 43 (31.39%) |  |
Menopausal status | Â | Â | Â | 0.522 | Â | Â | 0.453 |
 Pre-menopause | 148 | 107 (72.29%) | 41 (27.71%) |  | 97 (65.54%) | 51 (34.46%) |  |
 Post-menopause | 143 | 98 (68.53%) | 45 (31.47%) |  | 100 (69.93%) | 43 (30.07%) |  |
Family History | Â | Â | Â | 0.785 | Â | Â | 1 |
 Negative | 275 | 193 (70.18%) | 82 (29.82%) |  | 186 (67.63%) | 89 (32.37%) |  |
 Positive | 16 | 12 (75%) | 4 (25%) |  | 11 (68.75%) | 5 (31.25%) |  |
Histological grade | Â | Â | Â | 0.009 | Â | Â | 0.743 |
 I | 1 | 0 (0%) | 1 (100%) |  | 1 (100%) | 0 (0%) |  |
 II | 84 | 50 (59.52%) | 34 (40.48%) |  | 58 (69.04%) | 26 (30.96%) |  |
 III | 206 | 155 (75.24%) | 51 (24.76%) |  | 138 (66.99%) | 68 (33.01%) |  |
Tumor size | Â | Â | Â | 0.322 | Â | Â | 0.483 |
 pT1 | 136 | 89 (65.44%) | 47 (34.56%) |  | 91 (66.91%) | 45 (33.09%) |  |
 pT2 | 139 | 105 (75.53%) | 34 (24.47%) |  | 95 (68.34%) | 44 (31.66%) |  |
 pT3 | 12 | 8 (66.66%) | 4 (33.34%) |  | 7 (58.33%) | 5 (41.67%) |  |
 pT4 | 4 | 3 (75%) | 1 (25%) |  | 4 (100%) | 0 (0%) |  |
Nodal status | Â | Â | Â | 0.624 | Â | Â | 0.453 |
 Negative | 165 | 119 (72.12%) | 46 (27.88%) |  | 114 (69.09%) | 51 (30.91%) |  |
 1–3 nodes | 63 | 45 (71.42%) | 18 (28.58%) |  | 40 (63.49%) | 23 (36.51%) |  |
 4–9 nodes | 27 | 19 (70.37%) | 8 (29.63%) |  | 21 (77.77%) | 6 (22.23%) |  |
 ≥ 9 nodes | 36 | 22 (61.11%) | 14 (38.89%) |  | 22 (61.11%) | 14 (38.89%) |  |
TNM Stage | Â | Â | Â | 0.584 | Â | Â | 0.907 |
 I | 92 | 64 (69.56%) | 28 (30.44%) |  | 63 (68.47%) | 29 (31.53%) |  |
 II | 134 | 98 (73.13%) | 36 (26.87%) |  | 89 (66.41%) | 45 (33.59%) |  |
 III | 65 | 43 (66.15%) | 22 (33.85%) |  | 45 (69.23%) | 20 (30.77%) |  |
Basal phenotype | Â | Â | Â | 0.853 | Â | Â | 0.044 |
 Negative | 40 | 29 (72.5%) | 11 (27.5%) |  | 33 (82.5%) | 7 (17.5%) |  |
 Positive | 251 | 176 (70.11%) | 75 (29.89%) |  | 164 (65.33%) | 87 (34.67%) |  |
Ki67 indexa | Â | Â | Â | 0.036 | Â | Â | 0.84 |
 ≤ 14 | 30 | 16 (53.33%) | 14 (46.67%) |  | 21 (70%) | 9 (30%) |  |
 > 14 | 261 | 189 (72.41%) | 72 (27.59%) |  | 176 (67.43%) | 85 (32.57%) |  |
TIL | Â | Â | Â | 0.007 | Â | Â | 0.315 |
 Low | 153 | 97 (63.39%) | 56 (36.61%) |  | 108 (70.58%) | 45 (29.42%) |  |
 High | 138 | 108 (78.26%) | 30 (21.74%) |  | 89 (64.49%) | 49 (35.51%) |  |
LVI | Â | Â | Â | 1 | Â | Â | 0.146 |
 Negative | 270 | 190 (70.37%) | 80 (29.63%) |  | 186 (68.88%) | 84 (31.12%) |  |
 Positive | 21 | 15 (71.42%) | 6 (28.58%) |  | 11 (52.38%) | 10 (47.62%) |  |
Chemotherapy | Â | Â | Â | 0.682 | Â | Â | 0.842 |
 Negative | 32 | 24 (75%) | 8 (25%) |  | 21 (65.62%) | 11 (34.38%) |  |
 Positive | 259 | 181 (69.88%) | 78 (30.12%) |  | 176 (67.95%) | 83 (32.05%) |  |
Radiotherapy | Â | Â | Â | 0.895 | Â | Â | 0.305 |
 Negative | 179 | 127 (70.94%) | 52 (29.06%) |  | 117 (65.36%) | 62 (34.64%) |  |
 Positive | 112 | 78 (69.64%) | 34 (30.36%) |  | 80 (71.42%) | 32 (28.58%) |  |